Related Experiment Video
Updated: Mar 5, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
17.2K
Novel concepts for risk stratification in prostate cancer
Keval M Patel1, Vincent J Gnanapragasam2
1Cancer Research UK Cambridge Institute, University of Cambridge, UK; Academic Urology Group, University of Cambridge, UK.
Journal of Clinical Urology
|March 28, 2017
Summary
New tools improve prostate cancer risk stratification. This review details advances in biopsy, imaging, and biomarkers to aid treatment decisions for localized prostate cancer.
Area of Science:
- Oncology
- Urology
Background:
- Traditional prostate cancer risk stratification relies on prostate-specific antigen (PSA), clinical T-stage, and Gleason scores.
- Understanding of risk factors has evolved, leading to numerous new risk stratification tools.
Purpose of the Study:
- To outline novel concepts in risk stratification for localized prostate cancer.
- To identify techniques and tools likely for adoption in clinical practice.
Main Methods:
- Review of current literature on prostate cancer risk stratification.
- Analysis of novel biopsy strategies, imaging modalities, and biomarkers.
- Evaluation of various risk stratification tools (nomograms, artificial neural networks, etc.).
Main Results:
- Multiple advanced risk stratification tools are now available.
- Novel biopsy techniques, imaging, and biomarkers aim to enhance accuracy.
- Integration of these advances into clinical practice presents challenges.
Conclusions:
- Accurate pre-diagnosis, pre-treatment risk stratification is crucial for localized prostate cancer.
- Novel approaches promise improved treatment decisions.
- This article guides clinicians in adopting new risk stratification methods.
